Daraxonrasib plus chemotherapy shows promising first-line activity in RAS-mutant metastatic pancreatic cancer

ZL-1310 shows promising activity in DLL3-positive neuroendocrine carcinomas

DLL3 expression in circulating tumour cells predicts response to tarlatamab in small cell lung cancer

Tumour-selective oncolytic adenovirus LOAd703 with chemo shows immune activation and promising responses in pancreatic cancer

Oncolytic adenovirus VCN-01 plus chemo shows promising survival benefit in metastatic pancreatic cancer

ctDNA predicts early treatment response in HPV-associated anal cancer

Trastuzumab and tucatinib enable organ preservation in HER2-positive rectal cancer

Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC

The potential of T-cell engagers in SCLC treatment

Development and challenges for T-cell engagers as a novel treatment for lung cancer and mesothelioma

Cemiplimab shows durable 6-year survival benefit in PD-L1 high advanced NSCLC

MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung cancer